Hongfan Zhao, Dashan Wu, Michael Adu Gyamfi, Pinchao Wang, Christian Luecht, Anna Maria Pfefferkorn, Muhammad Imtiaz Ashraf, Julian Kamhieh-Milz, Janusz Witowski, Duska Dragun, Klemens Budde, Ralf Schindler, Daniel Zickler, Guido Moll, Rusan Catar
AIMS: Expanded hemodialysis (HDx) therapy with improved molecular cut-off dialyzers exerts beneficial effects on lowering uremia-associated chronic systemic microinflammation, a driver of endothelial dysfunction and cardiovascular disease (CVD) in hemodialysis (HD) patients with end-stage renal disease (ESRD). However, studies on the underlying molecular mechanisms are still at an early stage. Here, we identify the (endothelial) transcription factor Krüppel-like factor 2 (KLF2) and its associated molecular signalling pathways as key targets and regulators of uremia-induced endothelial micro-inflammation in the HD/ESRD setting, which is crucial for vascular homeostasis and controlling detrimental vascular inflammation...
2023: Frontiers in Immunology